Year: 2008
Type: article
Abstract: To the Editor: The use of sunitinib, an inhibitor of the split-kinase-domain family of receptor tyrosine kinases (including vascular endothelial growth factor receptor types 1 and 21), has been ass...
Source: New England Journal of Medicine
DOI: 10.1056/nejmc072330
Authors: Michel Azizi, Antoine Chedid, Stéphane Oudard
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2038827789
